Adverse drug reactions: Definitions, diagnosis, and management

Lancet

Volumn 356, Issue 9237, 2000, Pages 1255-1259

  Edwards, I Ralph ^a   Aronson, Jeffrey K ^b  

^a UPPSALA MONITORING CENTRE   (Sweden)

^b RADCLIFFE INFIRMARY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIGOXIN; OPIATE; ORAL CONTRACEPTIVE AGENT; PENICILLIN G; TRICYCLIC ANTIDEPRESSANT AGENT;

ADVERSE DRUG REACTION; CORTICOSTEROID THERAPY; DIFFERENTIAL DIAGNOSIS; DISEASE CLASSIFICATION; DISEASE COURSE; DOSE RESPONSE; DRUG HYPERSENSITIVITY; DRUG WITHDRAWAL; HUMAN; MEDICAL DECISION MAKING; MEDICAL INFORMATION; NOMENCLATURE; PATIENT EDUCATION; PATIENT MONITORING; PRIORITY JOURNAL; REVIEW; RISK BENEFIT ANALYSIS; SUBSTITUTION THERAPY; TREATMENT FAILURE; TREATMENT PLANNING;

EID: 0034619028     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(00)02799-9     Document Type: Article

References (24)

1. Definitions and classifications of adverse reaction terms
2. Errors in prescribing, preparing, and giving medicines - Definition, classification, and prevention
3. Incidence of adverse drug events and potential adverse drug events. Implications for prevention. ADE Prevention Study Group
4. Basic requirements for the use of terms for reporting adverse drug reactions
5. The medical dictionary for drug regulatory affairs (MEDDRA)
6. Pathogenesis of adverse drug reactions
7. Pathogenesis of adverse drug reactions
8. Adverse drug reactions
9. Mechanism of action of adverse drug reactions: An overview
10. Inclusion of therapeutic failures as adverse drug reactions
11. The diagnosis of adverse medical events associated with drug treatment
12. Computer-assisted evaluation of adverse events using a Bayesian approach
13. Causality classification at pharmacovigilance centres in the European Community
14. The WHO International Drug Monitoring Programme
15. Adverse drug reaction on-line information tracking (ADROIT)
16. Technological developments with the FDA adverse drug reaction file system
17. What are we doing in medicines safety? A perspective from the Uppsala Monitoring Centre
18. Incidence of adverse reactions in hospitalised patients
19. Reporting of adverse drug reactions by hospital pharmacists: Pilot scheme